ArticleStereotactic and functional neurosurgery2026
Imaging Changes and Clinical Outcome after MR-Guided Laser Interstitial Thermal Therapy.
Article in Stereotactic and functional neurosurgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
<p>Introduction: MR-guided laser interstitial thermal therapy (MRgLITT) is a minimally invasive technique for treating deep-seated brain lesions. However, the dynamics of imaging changes that occur after the ablation are not well characterized. This study aimed to describe the clinical outcomes and volume changes that occur over time after MRgLITT.
methodsWe retrospectively collected clinical and imaging data of all adult patients who underwent MRgLITT of brain tumors (primary and metastatic) between 01/2020 and 06/2024. Volumes and diameters of the lesions were measured on gadolinium-enhanced T1-weighted images using Brainlab Elements. Local control was assessed at the last follow-up.
resultsTwenty-nine patients with 32 treated lesions were available for assessment. Most lesions (n = 21) were metastatic, while 11 lesions were gliomas. The mean follow-up period was 23.4 ± 13.1 months. The average preoperative tumor volume was 2.8 ± 1.8cc. Post-ablation, the lesions' volumes increased on average by 250% (up to 450%) in the first month after surgery compared to the preoperative volumes. The enhancing ring extended distally beyond the tip of the catheter for an average of 4.5 ± 1.8 mm. Glial lesions had a median progression-free survival of 8.5 months. The volume of metastatic lesions decreased below the preoperative volume on average 3 months after surgery. Local control was achieved in 16 of 21 metastatic lesions (76%) and was significantly better for lesions smaller than 4cc in volume and 16 mm in maximal diameter that could be completely covered by the thermal damage estimation. Nodular enhancement at 3 months post-surgery was correlated with local failure.
conclusionMRgLITT can achieve good local control in metastatic brain lesions and should be considered early during follow-up after radiosurgery when local failure is suspected. The enhancing lesion extends beyond the tip of the catheter and enlarges during the first month post-ablation before gradually decreasing in size. Failure to decrease in size after 3 months or appearance of a nodular enhancement should raise suspicion of local failure. </p>.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.